Inhibitex acquired by Bristol-Myers Squibb

被引：0

作者：

Bruce, Issac

机构：

来源：

BIOANALYSIS | 2012年 / 4卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

收藏

页码：351 / 351

页数：1

相关论文

共 50 条

[21] AstraZeneca (Sweden)/Bristol-Myers Squibb (UK)
不详
JOURNAL OF DIABETES, 2009, 1 (04) : 232 - 233
[22] BRISTOL-MYERS SQUIBB BUILDS BIOLOGICS PLANT
不详
CHEMICAL & ENGINEERING NEWS, 2014, 92 (47) : 14 - 14
[23] Is Aventis following in the footsteps of Bristol-Myers Squibb?
不详
ANNALS OF ONCOLOGY, 2002, 13 (07) : 989 - 989
[24] The patient labeling program at Bristol-Myers Squibb
O'Connell, CA
Skinner, R
DRUG INFORMATION JOURNAL, 1999, 33 (03): : 649 - 654
[25] Technology evaluation: Abatacept, bristol-myers squibb
Dumont, FJ
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (03) : 318 - 330
[26] Bristol-Myers Squibb to buy tech center
不详
CHEMICAL & ENGINEERING NEWS, 1997, 75 (26) : 20 - 20
[27] Bristol-Myers Squibb rapped over generics
不详
CHEMISTRY & INDUSTRY, 2003, (06) : 7 - 7
[28] Bristol-Myers Squibb strengthens commitment to hepatitis research
不详
DRUG NEWS & PERSPECTIVES, 1997, 10 (08) : 476 - 476
[29] Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
不详
BIOPHARM INTERNATIONAL, 2014, 27 (09) : 12 - 12
[30] Technology evaluation: Belatacept, Bristol-Myers Squibb
Vanhove, B
Soulillou, JP
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (04) : 384 - 393

← 1 2 3 4 5 →